Vertex Pharmaceuticals今天宣布其在研选择性NaV1.8抑制剂suzetrigine（VX-548）近日取得的多项重要进展与相关开发计划。美国FDA同意Vertex滚动提交suzetrigine用于治疗中度至重度急性疼痛的新药申请（NDA）。Vertex已启动滚动提交流程，有望在2024年第二季度完成提交。

2025年3月28日，Vertex Pharmaceuticals宣布终止其第二代1型糖尿病（T1D）细胞疗法VX-264的研发，这一消息无疑为糖尿病治疗领域的创新尝试蒙上了一层阴影。 尽管如此，Vertex并未放弃对糖尿病治疗的探索，其另一款疗法VX-880（zimislecel）仍在积极推进中，并已进入III期 ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...

BOSTON, July 14, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term ...